September, 2006
Volume 4, Issue 2
 
Français arrow Home arrow PDF Version (2.8 MB) arrow Past Issues arrow Contact us arrow
 
In This Issue
Electronic Health Records
divider

Canada Health Infowayarrow

Company Profiles Research Institute Profile Ask an Investorarrow
Ask a Regulatory Expertarrow
Ask an Interoperability Expertarrow

Market Report Highlightsarrow
Patents Updatearrow

Upcoming Eventsarrow
Useful Linksarrow

divider


Editor-in-Chief
  • Katherine Taverner
Editors
  • Drew de Kergommeaux
  • Roxanne Deslauriers
  • Landis Henry
  • Vera Keown
  • Graham North
  • Louis Renaud
  • Joe Wery

bottom margin
  ISSN: 1712-3518
 

Ask an Investor

 

Q I’ve been told to provide an assessment of the competition in the market, what does this mean?

AWhen completing an assessment of the competition for your product that is in development there are a number of factors to consider. It is critical to have a clearly defined market and product definition to enable this analysis. It is important to evaluate both existing products and those in development to prevent bringing a product to market that doesn’t have a clear competitive advantage.

A common mistake made by many startup companies is not to include products that approach the problem in completely different ways. For example, someone that is developing a diagnostic product based on a PCR assay might only include other PCR based assays in their analysis rather than including ELISA or mass spectrometry based assays. An advantage of looking broadly for what might be competition can be that potentially new uses or markets for your product or product derivatives can be identified.


divider

Q The VC I talked with sounds interested and said they were going to start due diligence soon, how long before funding flows?

A A lot longer than you might think. Before making an investment, VCs will want to carefully look at your company and technology. The due diligence process usually lasts for several months and will involve a very deep look into your company, its finances, management, sustainable advantage, corporate structure, intellectual property, plans, assumptions, etc. The good news is that most VC’s enter due diligence thinking they would like to do the deal. But do expect the VC to look at everything very carefully and ask you to fix whatever is not in order.


Dr. Fast

Darren Fast, Ph.D.
President
Solalta Advisors
49 Nutley Circle
Winnipeg, MB R2N 1S2
204-229-8831
dfast@solalta.com
www.solalta.com


Do you have questions on investment options? Send your questions to Katherine Taverner


Copyright 2006 Medical Technology Watch Canada spacer National Research Council